Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK3 | P49761 | 19/20 | 0.76 |
| ▸ | CLK2 | P49760 | 18/20 | 0.76 |
| ▸ | DYRK1A | Q13627 | 18/20 | 0.76 |
| ▸ | WNT1 | P04628 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20965695 | 0.94 | WNT1 (0.68) | CLK3CLK2DYRK1AWNT1 | |
| SCHEMBL20966178 | 0.93 | CLK2 (0.73) | CLK3CLK2DYRK1AWNT1 | |
| SCHEMBL20965771 | 0.92 | CLK3 (0.65) | CLK3CLK2DYRK1AWNT1 | |
| SCHEMBL20966141 | 0.91 | WNT1 (0.78) | CLK3CLK2DYRK1AWNT1 | |
| SCHEMBL18441464 | 0.91 | CLK2 (0.75) | CLK3CLK2DYRK1AWNT1 | |
| SCHEMBL20965832 | 0.91 | CLK3 (0.74) | CLK3CLK2DYRK1AWNT1 | |
| SCHEMBL20965743 | 0.91 | CLK3 (0.68) | CLK3CLK2DYRK1AWNT1 | |
| SCHEMBL20966116 | 0.91 | CLK2 (0.63) | CLK3CLK2DYRK1AWNT1 | |
| SCHEMBL12370400 | 0.91 | CLK2 (0.68) | CLK3CLK2DYRK1AWNT1 | |
| SCHEMBL20965759 | 0.90 | CLK3 (0.74) | CLK3CLK2DYRK1AWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10285983-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-05-14 | — | — | US | claimed |
| US-20230000842-A1 | METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2023-01-05 | — | — | US | disclosed |
| US-10285983-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-05-14 | — | — | US | disclosed |
| US-10285983-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10285983-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof | WNT1, WNT3A, WNT3 | CLK3 2290/4885CLK2 2043/4885DYRK1A 849/4885 |
| US-20230000842-A1 | METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK | CLK2, CLK3, CLK1 | CLK3 2/4885CLK2 1/4885DYRK1A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.